The Many Roles of Cholesterol in Sepsis: A Review (original) (raw)

Abstract

The biological functions of cholesterol are diverse, ranging from cell membrane integrity, cell membrane signaling, and immunity to the synthesis of steroid and sex hormones, vitamin D, bile acids, and oxysterols. Multiple studies have demonstrated hypocholesterolemia in sepsis, the degree of which is an excellent prognosticator of poor outcomes. However, the clinical significance of hypocholesterolemia has been largely unrecognized. We undertook a detailed review of the biological roles of cholesterol, the impact of sepsis, its reliability as a prognosticator in sepsis, and the potential utility of cholesterol as a treatment. Sepsis affects cholesterol synthesis, transport, and metabolism. This likely impacts its biological functions, including immunity, hormone and vitamin production, and cell membrane receptor sensitivity. Early preclinical studies show promise for cholesterol as a pleiotropic therapeutic agent. Hypocholesterolemia is a frequent condition in sepsis and an important early prognosticator. Low plasma concentrations are associated with wider changes in cholesterol metabolism and its functional roles, and these appear to play a significant role in sepsis pathophysiology. The therapeutic impact of cholesterol elevation warrants further investigation.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (99)

  1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-810.
  2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990- 2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395:200-211.
  3. Macadam W, Shiskin C. The cholesterol content of the blood in relation to genito-urinary sepsis. Proc R Soc Med 1924;17:53-55.
  4. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2008;9:125-138.
  5. Shen WJ, Asthana S, Kraemer FB, Azhar S. Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function. J Lipid Res 2018;59:1114-1131.
  6. Jafurulla M, Chattopadhyay A. Membrane lipids in the function of serotonin and adrenergic receptors. Curr Med Chem 2013;20:47-55.
  7. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007;8:128-140.
  8. Morin EE, Guo L, Schwendeman A, Li XA. HDL in sepsis: risk factor and therapeutic approach. Front Pharmacol 2015;6:244.
  9. Guo L, Ai J, Zheng Z, Howatt DA, Daugherty A, Huang B, et al. High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem 2013;288:17947-17953.
  10. Varshney P, Yadav V, Saini N. Lipid rafts in immune signalling: current progress and future perspective. Immunology 2016;149:13-24.
  11. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25: 947-970.
  12. Borkowski AJ, Levin S, Delcroix C, Mahler A, Verhas V. Blood cholesterol and hydrocortisone production in man: quantitative aspects of the utilization of circulating cholesterol by the adrenals at rest and under adrenocorticotropin stimulation. J Clin Invest 1967;46:797-811.
  13. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014;21:319-329.
  14. Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ. Bile acids in physiology, pathology and pharmacology. Curr Drug Metab 2015;17: 4-29.
  15. Mutemberezi V, Guillemot-Legris O, Muccioli GG. Oxysterols: from cholesterol metabolites to key mediators. Prog Lipid Res 2016;64: 152-169.
  16. Spann NJ, Glass CK. Sterols and oxysterols in immune cell function. Nat Immunol 2013;14:893-900.
  17. Abrams ME, Johnson KA, Perelman SS, Zhang LS, Endapally S, Mar KB, et al. Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol. Nat Microbiol 2020;5: 929-942.
  18. Perucha E, Melchiotti R, Bibby JA, Wu W, Frederiksen KS, Roberts CA, et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nat Commun 2019;10:498.
  19. Golucci APBS, Marson FAL, Ribeiro AF, Nogueira RJN. Lipid profile associated with the systemic inflammatory response syndrome and sepsis in critically ill patients. Nutrition 2018;55-56:7-14.
  20. Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ. Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003;31:1647-1653.
  21. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359-1366.
  22. Levels JH, Pajkrt D, Schultz M, Hoek FJ, van Tol A, Meijers JC, et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007;1771: 1429-1438.
  23. Cirstea M, Walley KR, Russell JA, Brunham LR, Genga KR, Boyd JH. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J Crit Care 2017;38:289-294.
  24. Lekkou A, Mouzaki A, Siagris D, Ravani I, Gogos CA. Serum lipid profile, cytokine production, and clinical outcome in patients with severe sepsis. J Crit Care 2014;29:723-727.
  25. Lee SH, Park MS, Park BH, Jung WJ, Lee IS, Kim SY, et al. Prognostic implications of serum lipid metabolism over time during sepsis. BioMed Res Int 2015;2015:789298.
  26. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005;33:1688-1693.
  27. Walley KR, Boyd JH, Kong HJ, Russell JA. Low low-density lipoprotein levels are associated with, but do not causally contribute to, increased mortality in sepsis. Crit Care Med 2019;47:463-466.
  28. Vavrova L, Rychlikova J, Mrackova M, Novakova O, Zak A, Novak F. Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin. Clin Exp Med 2016;16:557-569.
  29. Trinder M, Genga KR, Kong HJ, Blauw LL, Lo C, Li X, et al. Cholesteryl ester transfer protein influences high-density lipoprotein levels and survival in sepsis. Am J Respir Crit Care Med 2019;199:854-862.
  30. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039-1044.
  31. van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994;84:1434-1441.
  32. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993;132:2246-2253.
  33. Hill NE, Saeed S, Phadke R, Ellis MJ, Chambers D, Wilson DR, et al. Detailed characterization of a long-term rodent model of critical illness and recovery. Crit Care Med 2015;43:e84-e96.
  34. Morel J, Hargreaves I, Brealey D, Neergheen V, Backman JT, Lindig S, et al. Simvastatin pre-treatment improves survival and mitochondrial function in a 3-day fluid-resuscitated rat model of sepsis. Clin Sci (Lond) 2017;131:747-758.
  35. Moreira RS, Irigoyen M, Sanches TR, Volpini RA, Camara NO, Malheiros DM, et al. Apolipoprotein A-I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis. Am J Physiol Regul Integr Comp Physiol 2014;307:R514-R524.
  36. Ettinger WH, Miller LD, Albers JJ, Smith TK, Parks JS. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res 1990;31:1099-1107.
  37. El-Deeb WM, Tharwat M. Lipoproteins profile, acute phase proteins, proinflammatory cytokines and oxidative stress biomarkers in sheep with pneumonic pasteurellosis. Comp Clin Pathol 2015;24:581-588.
  38. Hardy JP, Streeter EM, DeCook RR. Retrospective evaluation of plasma cholesterol concentration in septic dogs and its association with morbidity and mortality: 51 cases (2005-2015). J Vet Emerg Crit Care (San Antonio) 2018;28:149-156.
  39. Ali Abdelhamid Y, Cousins CE, Sim JA, Bellon MS, Nguyen NQ, Horowitz M, et al. Effect of critical illness on triglyceride absorption. JPEN J Parenter Enteral Nutr 2015;39:966-972.
  40. de Vasconcelos PR, Kettlewell MG, Gibbons GF, Williamson DH. Increased rates of hepatic cholesterogenesis and fatty acid synthesis in septic rats in vivo: evidence for the possible involvement of insulin. Clin Sci (Lond) 1989;76:205-211.
  41. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012;222:390-394.
  42. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015;15:104-116.
  43. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-1515.
  44. Dusuel A, Deckert V, Pais de Barros JP, van Dongen K, Choubley H, Charron E, et al. Human cholesteryl ester transfer protein lacks lipopolysaccharide transfer activity, but worsens inflammation and sepsis outcomes in mice. J Lipid Res [online ahead of print] 15 Dec 2020; DOI: 10.1194/jlr.RA120000704.
  45. Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, et al. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010;40:330-338.
  46. Trinder M, Wang Y, Madsen CM, Ponomarev T, Bohunek L, Daisely BA, et al. Inhibition of cholesteryl ester transfer protein preserves high- density lipoprotein cholesterol and improves survival in sepsis. Circulation 2021;143:921-934.
  47. Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 2014;6:258ra143.
  48. Feng Q, Wei WQ, Chaugai S, Carranza Leon BG, Kawai V, Carranza Leon DA, et al. A genetic approach to the association between PCSK9 and sepsis. JAMA Netw Open 2019;2:e1911130.
  49. Vecchi e A, Bonaventura A, Meessen J, Novelli D, Minetti S, Elia E, et al.; ALBIOS Biomarkers Study Investigators. PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. J Intern Med 2021;289:179-192.
  50. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, et al. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J Lipid Res 2009;50: 2258-2264.
  51. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, et al. Overexpression of secretory phospholipase A 2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem 2000; 275:10077-10084.
  52. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity: a clue to serum amyloid A's principal function. Lab Invest 1992;66:778-785.
  53. Bhogal HK, Sanyal AJ. The molecular pathogenesis of cholestasis in sepsis. Front Biosci (Elite Ed) 2013;5:87-96.
  54. Recknagel P, Gonnert FA, Westermann M, Lambeck S, Lupp A, Rudiger A, et al. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 2012;9:e1001338.
  55. Solomkin JS, Robinson CT, Cave CM, Ehmer B, Lentsch AB. Alterations in membrane cholesterol cause mobilization of lipid rafts from specific granules and prime human neutrophils for enhanced adherence- dependent oxidant production. Shock 2007;28:334-338.
  56. White MM, Geraghty P, Hayes E, Cox S, Leitch W, Alfawaz B, et al. Neutrophil membrane cholesterol content is a key factor in cystic fibrosis lung disease. EBioMedicine 2017;23:173-184.
  57. D€ unser MW, Ruokonen E, Pettil€ a V, Ulmer H, Torgersen C, Schmittinger CA, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009;13:R181.
  58. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res 2014;103:372-383.
  59. Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 2011;187:1529-1535.
  60. Hillyard DZ, Nutt CD, Thomson J, McDonald KJ, Wan RK, Cameron AJ, et al. Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis 2007; 191:319-325.
  61. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al.; American College of Critical Care Medicine. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008;36:1937-1949.
  62. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock: an update. Front Endocrinol (Lausanne) 2016;7:70.
  63. Kanczkowski W, Tymoszuk P, Chavakis T, Janitzky V, Weirich T, Zacharowski K, et al. Upregulation of TLR2 and TLR4 in the human adrenocortical cells differentially modulates adrenal steroidogenesis. Mol Cell Endocrinol 2011;336:41-46.
  64. Haeno S, Maeda N, Yamaguchi K, Sato M, Uto A, Yokota H. Adrenal steroidogenesis disruption caused by HDL/cholesterol suppression in diethylstilbestrol-treated adult male rat. Endocrine 2016;52:148-156.
  65. Festti J, Grion CM, Festti L, Mazzuco TL, Lima-Valassi HP, Brito VN, et al. Adrenocorticotropic hormone but not high-density lipoprotein cholesterol or salivary cortisol was a predictor of adrenal insufficiency in patients with septic shock. Shock 2014;42:16-21.
  66. Molenaar N, Bijkerk RM, Beishuizen A, Hempen CM, de Jong MF, Vermes I, et al. Steroidogenesis in the adrenal dysfunction of critical illness: impact of etomidate. Crit Care 2012;16:R121.
  67. Etogo-Asse FE, Vincent RP, Hughes SA, Auzinger G, Le Roux CW, Wendon J, et al. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver Int 2012;32:128-136. [Published erratum appears in Liver Int 32:523.]
  68. Arem R, Ghusn H, Ellerhorst J, Comstock JP. Effect of decreased plasma low-density lipoprotein levels on adrenal and testicular function in man. Clin Biochem 1997;30:419-424.
  69. de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care 2014; 18:660.
  70. Christaki E, Opal SM, Keith JC Jr, Kessinian N, Palardy JE, Parejo NA, et al. Estrogen receptor b agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study. J Infect Dis 2010;201:1250-1257.
  71. Amrein K, Schnedl C, Holl A, Riedl R, Christopher KB, Pachler C, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA 2014;312:1520-1530.
  72. Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, et al.; National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients. N Engl J Med 2019;381: 2529-2540.
  73. Christeff N, Benassayag C, Carli-Vielle C, Carli A, Nunez EA. Elevated oestrogen and reduced testosterone levels in the serum of male septic shock patients. J Steroid Biochem 1988;29:435-440.
  74. Horvatits T, Drolz A, Rutter K, Roedl K, Langouche L, Van den Berghe G, et al. Circulating bile acids predict outcome in critically ill patients. Ann Intensive Care 2017;7:48.
  75. Kipp HA. Variation in the cholesterol content of the serum in pneumonia. J Biol Chem 1920;44:215-237.
  76. Press AT, Traeger A, Pietsch C, Mosig A, Wagner M, Clemens MG, et al. Cell type-specific delivery of short interfering RNAs by dye- functionalised theranostic nanoparticles. Nat Commun 2014;5:5565.
  77. Song Z, Bai J, Nauwynck H, Lin L, Liu X, Yu J, et al. 25- Hydroxycholesterol provides antiviral protection against highly pathogenic porcine reproductive and respiratory syndrome virus in swine. Vet Microbiol 2019;231:63-70.
  78. McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 2003;20:551-557.
  79. Zhang Z, Datta G, Zhang Y, Miller AP, Mochon P, Chen YF, et al. Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol 2009;297:H866-H873.
  80. Datta G, Gupta H, Zhang Z, Mayakonda P, Anantharamaiah GM, White CR. HDL mimetic peptide administration improves left ventricular filling and cardiac output in lipopolysaccharide-treated rats. J Clin Exp Cardiolog 2011;2:1000172.
  81. Kwon WY, Suh GJ, Kim KS, Kwak YH, Kim K. 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg 2012;72:1576-1583.
  82. Zhang X, Wang L, Chen B. Recombinant HDL (Milano) protects endotoxin-challenged rats from multiple organ injury and dysfunction. Biol Chem 2015;396:53-60.
  83. Tanaka S, Gen eve C, Zappella N, Yong-Sang J, Planesse C, Louedec L, et al. Reconstituted high-density lipoprotein therapy improves survival in mouse models of sepsis. Anesthesiology 2020;132:825-838.
  84. Berger JM, Loza Valdes A, Gromada J, Anderson N, Horton JD. Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. J Lipid Res 2017;58:1661-1669.
  85. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996;184:1601-1608.
  86. Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, et al.; Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009;37:2929-2938.
  87. Guirgis FW, Black LP, Rosenthal MD, Henson M, Ferreira J, Leeuwenburgh C, et al. Lipid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock. BMJ Open 2019;9:e029348.
  88. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017;120:229-243.
  89. Zeiser R. Immune modulatory effects of statins. Immunology 2018;154: 69-75.
  90. Durant R, Klouche K, Delbosc S, Morena M, Amigues L, Beraud JJ, et al. Superoxide anion overproduction in sepsis: effects of vitamin e and simvastatin. Shock 2004;22:34-39.
  91. Camerino GM, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S. Statin-induced myopathy: translational studies from preclinical to clinical evidence. Int J Mol Sci 2021;22:2070.
  92. DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol 2015;7:404-409.
  93. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-418.
  94. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-79.
  95. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33: 1352-1357.
  96. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, et al.; ANZ-STATInS Investigators-ANZICS Clinical Trials Group. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013;187: 743-750.
  97. Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, et al.; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370:2191-2200.
  98. McAuley DF, Laffey JG, O'Kane CM, Perkins GD, Mullan B, Trinder TJ, et al.; HARP-2 Investigators; Irish Critical Care Trials Group. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014;371:1695-1703.
  99. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al.; Irish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 2018;6:691-698.